Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model

• Mamoudou Maiga ,

  Contributed equally to this work with: Mamoudou Maiga, Nisheeth Agarwal

  Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Nisheeth Agarwal ,

  Contributed equally to this work with: Mamoudou Maiga, Nisheeth Agarwal

  Affiliations Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, Vaccine and Infectious Disease Research Center, Translational Health Science and Technology Institute, Gurgaon, India

  ⨯
• Nicole C. Ammerman,

  Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Radhika Gupta,

  Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Haidan Guo,

  Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Marama C. Maiga,

  Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• Shichun Lun,

  Affiliation Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America

  ⨯
• William R. Bishai

  * E-mail: wbishai1@jhmi.edu

  Affiliations Center for Tuberculosis Research, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America, KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Durban, South Africa, Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America

  ⨯